Therapeutic effects of shibashin misena® against fine-dust-induced pulmonary disorders in mice

Biomed Pharmacother. 2020 May:125:110018. doi: 10.1016/j.biopha.2020.110018. Epub 2020 Feb 25.

Abstract

Introduction: In recent decades, fine-dust particulate matter (FM) has become a potential health hazard, causing various pathological respiratory disorders around the world. Inflammation induced by FM is regarded as a major cause of respiratory disorder in humans. The purpose of this study was to evaluate the therapeutic efficacy of Shibashin Misena®, a functional food composed of various bioactive ingredients, on FM-induced respiratory disorders in mice.

Materials and methods: Briefly, 40 mice were divided equally into four groups: normal controls (NC); FM-induced control group (FC); FM group treated with Shibashin Misena® 0.1 mL/head/day (FM0.1); FM group treated with Shibashin Misena® 0.2 mL/head/day (FM0.2).

Results: FM significantly induced TNF-α, IL-17A, IL-1β, and TGF-β in bronchoalveolar lavage fluid (BALF) collected from the FM mice. Compared with FC, Shibashin Misena® decreased TNF-α, IL-17A, and IL-1β levels in BALF, and histopathologic evaluations revealed that Shibashin Misena® treatment significantly reduced inflammatory-cell infiltration and fibrosis related collagen deposition in lung tissue.

Conclusion: This study demonstrated that Shibashin Misena® decreased FM-induced inflammation and fibrosis in lung tissue. Thus, Shibashin Misena® could be an effective supplement to prevent or improve FM-induced pulmonary disorders.

Keywords: Fibrosis; Fine-dust particulate matter; Inflammation; Pulmonary disorders; Shibashin misena®.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / administration & dosage
  • Biomarkers
  • Cytokines / metabolism
  • Disease Management
  • Disease Models, Animal
  • Disease Susceptibility
  • Dust*
  • Functional Food*
  • Immunohistochemistry
  • Inflammation Mediators / metabolism
  • Lung Diseases / diet therapy*
  • Lung Diseases / etiology*
  • Lung Diseases / metabolism
  • Lung Diseases / pathology
  • Mice
  • Particulate Matter / adverse effects*
  • Pulmonary Fibrosis / drug therapy
  • Pulmonary Fibrosis / etiology
  • Pulmonary Fibrosis / metabolism
  • Pulmonary Fibrosis / pathology

Substances

  • Anti-Inflammatory Agents
  • Biomarkers
  • Cytokines
  • Dust
  • Inflammation Mediators
  • Particulate Matter